Core Viewpoint - The company has reported an abnormal fluctuation in the trading of its convertible bonds, "塞力转债," with a cumulative price increase exceeding 30% over three consecutive trading days, prompting a reminder for investors to be cautious about valuation risks [1][7]. Group 1: Convertible Bond Issuance and Trading - The company issued 5.4331 million convertible bonds on August 21, 2020, with a face value of 100 yuan each, totaling 543.31 million yuan [2]. - The initial conversion price for "塞力转债" was set at 16.98 yuan per share, with the conversion period from March 1, 2021, to August 20, 2026 [2]. - The trading price of "塞力转债" reached 175.078 yuan per bond as of July 3, 2025, representing a premium of 75.08% over the face value and a conversion premium rate of 9.65% [1][7]. Group 2: Price Adjustments and Corporate Actions - The company has undergone multiple adjustments to the conversion price of "塞力转债," with the latest adjustment reducing the price from 12.50 yuan to 12.00 yuan per share, effective from February 2025 [5]. - The company confirmed that there are no undisclosed significant events affecting the trading of its convertible bonds, including major asset restructuring or significant transactions [6]. Group 3: Operational Status and Market Environment - The company reported that its production and operational activities are normal, with no significant changes in the market environment or industry policies that could impact the trading of its convertible bonds [6]. - The company has not identified any major events or media reports that could significantly influence the trading price of its convertible bonds [6].

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-059 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于"塞力转债"交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： "塞力转债"于2025年7月1日、7月2日、7月3日连续3个交易日收盘价格 涨幅偏离值累计超过30%，根据《上海证券交易所可转换公司债券交易实施细则》 的相关规定，属于可转债交易异常波动情况。 截至2025年7月3日收盘，"塞力转债"收盘价格为175.078元/张，相对 于票面价格溢价75.08%，转股溢价率9.65%。敬请广大投资者注意当前估值风险， 理性投资。 经公司自查，并向控股股东赛海（上海）健康科技有限公司（以下简称 "赛海科技"）及实际控制人温伟先生发函核实，截至本公告披露日，控股股东 及实际控制人不存在应披露而未披露的重大信息，包括但不限于重大资产重组、 股份发行、重大交易类事项、业务重组、股份回购、 ...

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-058 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于控股股东、实际控制人部分股份 解除质押及股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 塞力斯医疗科技集团股份有限公司（以下简称"公司"）控股股东赛海 （上海）健康科技有限公司（以下简称"赛海科技"）持有公司 21,642,540 股 无限售条件流通股股票，占公司总股本的 11.33%（截至 2025 年 6 月 30 日总股 本，下同）。近日，赛海科技将其中 6,700,000 股股份办理了解除质押登记手续， 后将 6,000,000 股股份办理了质押登记手续，本次新增质押为替换性质押。相关 手续办理完毕后，赛海科技累计质押公司股份 15,100,000 股，占其持有公司股 份比例为 69.77%，占公司总股本比例为 7.91%。 公司实际控制人温伟先生持有公司股份 9,6 ...

Core Viewpoint - The company announced that its convertible bond "Saili Convertible Bond" experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 30% over three consecutive trading days from July 1 to July 3, 2025 [1] Group 1 - The company's production and operational activities are normal, with no significant adjustments in market environment or industry policies [1] - The internal production and operational order of the company is stable [1] - The controlling shareholder and actual controller of the company do not have any undisclosed significant information that should have been disclosed [1]

New Stock Offerings - Jichuan Pharmaceutical (600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - *ST Yazhen (603389) has a tender offer period from June 10, 2025, to July 9, 2025[1] - Zhongcheng Tui (300208) has 11 trading days remaining until the last trading day[1] Delisting and Trading Reminders - Tui Shi Jin Gang (600190) has 11 trading days remaining until the last trading day[1] - Hengli Tui (000622) is in the delisting arrangement period with 8 trading days remaining[1] - Tui Shi Jiu You (600462) has 7 trading days remaining until the last trading day[1] Market Volatility - Beifang Changlong (301357) reported severe abnormal fluctuations[1] - Multiple companies, including Jichuan Pharmaceutical and *ST Yazhen, are under scrutiny for trading anomalies[1]

Core Viewpoint - The short-term sentiment in the market has improved, with a significant number of stocks reaching their upper limit, indicating a potential recovery in investor confidence [1] Group 1: Market Performance - A total of 61 stocks hit the daily limit, with 14 stocks classified as consecutive limit-up stocks, and 5 of these achieved three consecutive limit-ups or more [1] - The upgrade rate for consecutive limit-up stocks was 41.67%, excluding ST and delisted stocks [1] - Over 3,200 stocks in the market experienced an increase, reflecting a broad-based rally [1] Group 2: Notable Stocks - Chengbang Co. achieved a limit-up, marking its sixth consecutive limit-up [1] - Dazhongnan showcased a "ground-to-sky" performance with 8 limit-ups in 6 days [1] - Haoshanghao reached a historical high with 5 limit-ups over 7 days [1] Group 3: Sector Performance - The innovative drug sector led the market gains, with notable performances from companies like Innovent Biologics, which saw a rise of over 9% in Hong Kong [1] - In the A-share market, Selin Medical achieved three consecutive limit-ups, while Chengyi Pharmaceutical and Weiming Pharmaceutical recorded two and three limit-ups, respectively [1] - The PCB sector also showed strength, with Shenghong Technology increasing over 6%, surpassing a market capitalization of 120 billion, and Pengding Holdings hitting the limit-up [1]

Group 1 - The ChiNext index showed strong performance, rising over 1% with active participation from innovative drug and commercial aerospace concepts [1][2][3] - The ChiNext index rose by 1.36% at midday, with notable stocks such as Lens Technology (300433) increasing over 8% and Ningde Times (300750) nearly 4% [2][3] - The innovative drug concept saw significant gains, with multiple stocks hitting the daily limit, including ShenZhou Cell and Jiuzhitang [3][6] Group 2 - The Hong Kong stock market experienced a slight decline, with the Hang Seng Index dropping over 1% at one point [9] - Multi-point Intelligence saw its stock price surge, with an intraday increase nearing 90%, attributed to its plans for a stablecoin license [10][12] - The pharmaceutical sector in the Hong Kong market rose over 2%, with several stocks, including Huahao Zhongtian Pharmaceutical-B, increasing over 10% [12] Group 3 - JiXin Technology (601218) experienced its fourth consecutive trading day of hitting the daily limit, while issuing a risk warning regarding its high rolling P/E ratio of 72.85 compared to the industry average of 22.24 [7][8] - SaiLi Medical also hit the daily limit for the third consecutive day, with the company confirming no undisclosed significant information affecting its stock price [8]

A股创新药概念股延续强势，塞力医疗3连板，九芝堂、微芯生物涨超7%，长春高新、未名医药、佐力 药业纷纷拉升。 ...

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-057 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 塞力斯医疗科技集团股份有限公司（以下简称"公司"）股票连续3个交 易日内日收盘价格涨幅偏离值累计超过20%，根据《上海证券交易所交易规则》 的有关规定，属于股票交易异常波动情形。 经公司自查，并向控股股东赛海（上海）健康科技有限公司（以下简称 "赛海科技"）及实际控制人温伟先生发函核实，截至本公告披露日，控股股东 及实际控制人不存在应披露而未披露的重大信息，包括但不限于重大资产重组、 股份发行、重大交易类事项、业务重组、股份回购、破产重整、重大业务合作、 引进战略投资者等重大事项。 风险提示详见本公告"三、相关风险提示"，公司倡导价值投资并专注 于主业的发展，敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 一、股票交 ...

Core Viewpoint - The innovative drug sector continues to show strong performance, with companies like Sali Medical achieving consecutive gains, driven by supportive government policies aimed at enhancing the development of innovative drugs [1] Group 1: Market Performance - Sali Medical has achieved two consecutive trading gains [1] - Microchip Biotech has increased by over 10% [1] - Other companies such as Huahai Pharmaceutical, Weiming Pharmaceutical, Anglikang, and Yuekang Pharmaceutical also experienced upward movement [1] Group 2: Government Support - The National Healthcare Security Administration and the National Health Commission have issued measures to support the high-quality development of innovative drugs [1] - The measures include support for innovative drugs to enter the basic medical insurance drug list and the commercial health insurance innovative drug list [1] - The establishment of a commercial health insurance innovative drug list is also part of the new measures [1]